SCHEMBL6282533

SCHEMBL6282533

COc1ccc(-c2cc3ccncc3[nH]2)cc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
NTRK1 P04629 1/20 0.44
NR3C1 P04150 6/20 0.43
NR3C2 P08235 3/20 0.43
AURKA O14965 1/20 0.43
TTK P33981 1/20 0.43
AURKB Q96GD4 1/20 0.43
INCENP Q9NQS7 1/20 0.43
CLK2 P49760 1/20 0.42
CLK3 P49761 1/20 0.42
DYRK1A Q13627 1/20 0.42
PGR P06401 2/20 0.42
RIPK1 Q13546 1/20 0.41
NPY5R Q15761 1/20 0.41
CYP19A1 P11511 1/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
CASP3 P42574 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6286157 0.90 KDM4E (0.44) KDM4EALDH1A1HPGDNTRK1NR3C1
SCHEMBL6286924 0.85 CYP1A1 (0.44) KDM4EALDH1A1NTRK1AURKATTK
SCHEMBL6282531 0.82 IKBKB (0.47) KDM4EALDH1A1HPGDNR3C1NR3C2
SCHEMBL6503284 0.81 RAB9A (0.61) KDM4EALDH1A1HPGDCYP19A1NPC1
Hydrochloric Acid SCHEMBL6502726 0.80 RAB9A (0.60) KDM4EALDH1A1HPGDCYP19A1NPC1
SCHEMBL4782250 0.79 KDM4E (0.63) KDM4EALDH1A1HPGDCLK2CLK3
SCHEMBL20302793 0.79 KDM4E (0.46) KDM4EALDH1A1HPGDNTRK1NR3C1
SCHEMBL30166639 0.79 KDM4E (0.46) KDM4EALDH1A1HPGDNTRK1NR3C1
SCHEMBL6286092 0.78 ALDH1A1 (0.41) KDM4EALDH1A1HPGDNTRK1NR3C1
SCHEMBL6282773 0.78 ALDH1A1 (0.77) KDM4EALDH1A1HPGDAURKANPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US claimed
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US claimed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP claimed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO claimed
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US disclosed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP disclosed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014759-A1 6,5-Fused bicyclic heterocycles ALOX15, ALOX5, ALOX15B KDM4E 2221/4885ALDH1A1 522/4885HPGD 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.